Consequently, the blockade of the PD-1/PD-L1 or PD-L2 axis by antibodies such as Nivolumab (Opdivo®), Pembrolizumab (Keytruda®), or Cemiplimab (Libtayo®) has emerged as a promising strategy to restore the anti-tumor immune response. This evidence concerns the gene PDCD1 and neoplasm.